Novel CAR T cell therapy developed by UT MD Anderson researchers moves into clinical studies

May 15, 2026

The novel therapy targets CD94+ relapsed or refractory T/NK cell lymphomas
UT MD Anderson received Investigational New Drug clearance from the Food and Drug Administration to begin Phase 1 clinical trial

Read the full press release here: Dr. Neelapu JV394 CAR-T therapy IND Clearance

Recent Press Releases

CTMC and Einstein Hospital Israelita in Brazil Partner to Launch the Global Cell Therapy Network Alliance

Oct 2, 2025

The CTMC Network Alliance aims to democratize and accelerate cell therapies to cancer patients globally Read the full press release: CTMC - Einstein...

CTMC Appoints Amy Hay as Chief Business Officer and Duane Avant as Chief Technical Officer

Feb 5, 2025

HOUSTON, TX, February 5, 2025 — CTMC, a joint venture between Resilience and MD Anderson Cancer Center, has appointed Amy Hay as Chief Business...

CTMC and Syenex Launch Partnership to Accelerate Scalability of Cell Therapies

Jan 8, 2025

Houston, TX and Chicago, IL - January 8, 2025: CTMC, a joint venture between MD Anderson Cancer Center and Resilience, has entered a partnership...

Back

Novel CAR T cell therapy developed by UT MD Anderson researchers moves into clinical studies

Recent Press Releases

CTMC and Einstein Hospital Israelita in Brazil Partner to Launch the Global Cell Therapy Network Alliance

CTMC Appoints Amy Hay as Chief Business Officer and Duane Avant as Chief Technical Officer

CTMC and Syenex Launch Partnership to Accelerate Scalability of Cell Therapies

Explore CTMC

Resources + Support

Contact Us